AVEO Pharmaceuticals, Inc. to Present at Several Upcoming Investment Conferences
CAMBRIDGE, Mass., Nov 22, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the company's management will present a company overview at several upcoming investment conferences.
David Johnston, chief financial officer, is scheduled to present at the following event:
- 22nd Annual Piper Jaffray Health Care Conference on Wednesday, December 1, 2010 at 9:00 a.m. (EST) at the New York Palace Hotel in New York City.
Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the following events:
- J.P. Morgan Smid Cap Conference on Thursday, December 2, 2010 at 1:30 p.m. (EST) at the J.P. Morgan Conference Center in New York City.
- Deutsche Bank's 2010 BioFEST on Tuesday, December 14, 2010 at 3:35 p.m. (EST) at the Four Seasons Hotel in Boston.
Webcasts of AVEO's presentations can be accessed by visiting the investors section of the company's website at investor.aveopharma.com. A replay of the webcasts will be archived on the AVEO website for two weeks following each presentation date, respectively.
AVEO Pharmaceuticals (NASDAQ: AVEO) integrates a proprietary cancer biology platform with drug development and commercial expertise in its efforts to discover and develop targeted cancer therapeutics. The company's lead product, tivozanib, is an oral, triple VEGF receptor inhibitor with a highly differentiated profile. Tivozanib is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in advanced kidney cancer, as well as additional clinical studies in other solid tumor types. AVEO's second most advanced product candidate, AV-299, is a potent, functional anti-HGF antibody that is currently in Phase 2 development. AVEO's proprietary, integrated cancer biology platform offers the company a unique advantage in oncology drug development and has provided a discovery engine for high-value targets. This approach has resulted in a promising pipeline of monoclonal antibodies against novel targets including HGF, ErbB3, RON, Notch and FGFR. For more information, please visit the company's website at www.aveopharma.com.
SOURCE: AVEO Pharmaceuticals, Inc.
AVEO Pharmaceuticals, Inc.
Monique Allaire, 617-299-5810
Caton Lovett, 910-232-7166